Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 1Leukemia 1Hematologic Neoplasms 1Graft vs Host Disease 1

Interventions

Tacrolimus 37Methotrexate 27Cyclophosphamide 27Mycophenolic Acid 21fludarabine phosphate 19Busulfan 19Antilymphocyte Serum 19Cyclosporine 18Sirolimus 16Methylprednisolone 16fludarabine 15Peripheral Blood Stem Cell Transplantation 15Melphalan 14Filgrastim 13Radiotherapy 12Whole-Body Irradiation 8Granulocyte Colony-Stimulating Factor 8thymoglobulin 6Stem Cell Transplantation 6Rituximab 6Prednisone 6Pentostatin 6Hematopoietic Stem Cell Transplantation 5Etoposide 5ruxolitinib 4Thiotepa 4Flow Cytometry 4Cytarabine 4Cyclosporins 4Cord Blood Stem Cell Transplantation 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Graft vs Host Disease × Calcineurin Inhibitors × Clear all
NCT01379209 2019-10-23

Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)

Regimmune Corporation

Phase 1/2 Completed
68 enrolled
MyeloidOther hematologic neoplasm

Graft vs Host Disease, Leukemia, Myelodysplastic Syndromes, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡